This is an exciting time for research into the drug treatment of schizophrenia. Modern techniques in imaging and molecular biology have contributed to our understanding of the receptor mechanisms of antipsychotic drug action. Several new antipsychotics are, or will shortly be, available and each of these new drugs promise improvements over classical antipsychotics. This review will discuss the concept of atypicality in antipsychotic drugs, and will describe some of the models for identification of improved antipsychotic action. The various receptor mechanisms proposed to underlie atypical antipsychotic action, several of which have featured in recent debates in this journal, will be considered in the light of the pharmacology of some of the newly- emerging antipsychotic drugs.
Andén N.E., Grendhoff J., Svensson T.H. (1988) Does treatment with haloperidol for 3 weeks produce depolarization block in midbrain dopamine neurons of unanaesthetized rats?Psychopharmacology96:558-560
2.
Bakshi V., Geyer M.A. (1995) Antagonism of PCP-induced deficits prepulse inhibition by olanzapine. Soc Neurosci Abstr21:1707
3.
Blake T.J., Reynolds G.P. (1996) Antipsychotic drug action at α 2adrenoceptor subtypes in postmortem human brain. J Psychopharmac10 (Suppl.): A7
4.
Busatto G.F., Kerwin R.W. (1997) Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia. J Psychopharmac11:3-12
5.
Busatto G.F., Pilowsky L.S., Costa D.C., Ell P.J., Verhoeff N., Kerwin R.W. (1995) Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride—a 123I-IBZM single photon emission tomography (SPET) study. Psychopharmacology117: 55-61
6.
Casey D.E. (1993) Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology112: S55-S59
7.
Casey D.E., Gerlach J., Christensson E. (1980) Dopamine, acetylcholine, and GABA effects in acute dystonia in primates. Psychopharmacology70: 80-87
8.
Coffey I. (1994) Options for the treatment of negative symptoms of schizophrenia. CNS Drugs1:107-118
9.
Duinkerke S., Botter P., Jansen A. (1993) Ritanserin, a selective 5-HT2/lc antagonist, and negative symptoms in schizophrenia; a placebo-controlled double-blind trial . Br J Psychiat164: 451-455
10.
Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Archs Gen Psychiat49: 538-544
11.
Gefvert O., Lindstrom L.H., Langstrom B., Bergstrom M., Lundberg T., Yates R.A. (1996) Time course for dopamine and serotonin receptor occupancy in the brain of schizophrenic patients following dosing with 150mg 'Seroquel' TID. Eur Neuropsychopharmac6 (Suppl. 3): 74
12.
Gelders Y.G. (1989) Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br J Psychiat155 (Suppl. 5): 33-36
13.
Gerlach J. (1991) New antipsychotics: classification, efficacy and adverse effects. Schizophr Bull17: 289-309
14.
Goldstein J.M., Snyder D.H. (1995) Effects of Seroquel, clozapine and other putative atypical antipsychotic agents in primate models of dystonia. Schizophr Res15:152
15.
Kane J.M., Lieberman J. (1987) Maintenance pharmacotherapy in schizophrenia. In: Meltzer H Y (ed.), Psychopharmacology: the third generation of progress. Raven Press, New York, pp. 1103-1109
16.
Kane J.M., Honigfeld G., Singer J., Meltzer H.Y., and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic . Archs Gen Psychiat35: 789-796
17.
Kasper S.,TauscherJ., Kufferle B., Heiden A., NeumeisterA., Barnas C., Asenbaum S., Podreka I., Brucke T. (1996) D2-receptor imaging in atypical neuroleptics. Eur Neuropsychopharmac6 (Suppl. 3): 73
18.
Keepers G.A., Clappison V., Casey D.E. (1983) Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Archs Gen Psychiat40:1113-1117
19.
Kramer M., Zimbroff D., Last B., Getson A., D4 antagonist study group (1996) The effects of a selective D 4 antagonist (L-745,870) in acutely psychotic schizophrenic patients . Poster presentation 36th NCDEU, Boca Raton, FL
20.
Laux G., Kleiser E., Schroeder H.G., Dittman V., Unterweger B., Schubert H., Koenig P., Schoeny H.W., Bunse J., Beckmann H. (1990) A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia. Acta Psychiat Scand82 (Suppl. 358):125-129
21.
Litman R.E., Hong W.W., Weissman E.M., Su T.P., Potter W.Z., Pickar D. (1993) Idazoxan, an α2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study. J Clin Pharmac13: 264-267
22.
Litman R.E., SuT P, PotterW Z, HongW W, Pickar D. (1996) Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br J Psychiat168: 571-579
23.
Meltzer H.Y., Matsubara S., Lee J-C. (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pKi values. J Pharmac Exp Therap251: 238-246
24.
Migler B.M., Warawa E.J., Malick J.B. (1993) Seroquel: behavioural effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology112: 299-307
25.
Miller R.J., Hiley C.R. (1974) Antimuscarinic properties of neuroleptics and drug-induced Parkinsonism. Nature248: 596-597
26.
Needham P., Skill M.J., Heal D.J. (1995) Zotepine: preclinical tests predict antipsychotic efficacy and an atypical profile. Eur Neuropsychopharmac5: 331-332
27.
Nutt D.J. (1994) Putting the 'A' in atypical: does α2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics? J Psychopharmac8:193-195
28.
Pilowsky L.S., Busatto G.F., Taylor M., Costa D.C., Sharma T., Sigmundsson T., Ell P.J., Nohria V., Kerwin R.W. (1996) Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine-a 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology124:148-153
29.
Randrup A., Munkvad I. (1965) Special antagonism of amphetamine-induced abnormal behaviour. Psychopharmacologia7: 416-422
30.
Reynolds G.P. (1995) Neurotransmitter systems in schizophrenia. Int Rev Neurobiol38: 305-339
31.
Reynolds G.P. (1996) The importance of dopamine D4 receptors in the action and development of antipsychotic agents. Drugs51: 7-11
32.
Reynolds G.P., Cowey L., Rossor M., Iversen L.L. (1982) Thioridazine is not specific for limbic dopamine receptors. Lancetii: 499-500
33.
Reynolds G.P., Czudek C. (1995) New approaches to the drug treatment of schizophrenia . Adv Pharmac32: 461-503
34.
Robertson G.S., Matsumura H., Fibiger H.C. (1994) Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmac Exp Therap271: 1058-1066
35.
Schooler N.R. (1994) Negative symptoms in schizophrenia: assessment of the effect of risperidone. J Clin Psychiat55: S22-S28
36.
Seeman P., Lee T., Chau-Wong M., Wong K. ( 1976) Antipsychotic drug doses and neuroleptic/dopamine receptors . Nature261: 717-719
37.
Seymour P.A., Seeger T.F., Guanowsky V., Robinson G.L., Howard H., Heym J. ( 1993) Behavioural pharmacology of CP-88,059: a new antipsychotic with both 5-HT2 and D2 antagonist activities. Soc Neurosci Abstr19:1623
38.
Skarsfeldt T. (1992) Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurons in rats: acute and repeated treatment. Synapse10: 25-33
39.
Soni S.D., Malik A., Schiff A.A. (1990) Sulpiride in negative schizophrenia: a placebo-controlled double-blind assessment. Hum Psychopharmac5: 233-238
40.
Sorensen S.M., Kehne J.H., Fadayel G.M., Humphreys T.M., Ketteler H.J., Sullivan C.K., Taylor V.L., Schmidt C.J. (1993) Characterisation of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmac Exp Therap266: 684-691
41.
Stockton M.E., Rasmussen K. (1996) Electrophysiological effect of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology14: 97-104
42.
Swerdlow N., Bakshi V., Geyer M. (1996) Seroquel restores prepulse inhibition of startle in phencyclidine-treated rats. Eur Neuropsychopharmac6 (Suppl. 3):107
43.
Weinberger D. (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Archs Gen Psychiat44: 660-669
44.
White FJ, Wang RY ( 1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science221: 1054-1057
